ReviewJournal of clinical medicine2025
The Evaluation, Diagnosis, and Management of Infantile Hemangiomas-A Comprehensive Review.
Review in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A Systematic Review and Meta-Analysis of the Efficacy and Safety of Propranolol Versus Other Drugs in the Treatment of Infantile Hemangioma.Journal of cosmetic dermatology · 2026Pooled it
- Population Pharmacokinetics of Topical Timolol Maleate Gel in Healthy Volunteers and Infants With Superficial Infantile Hemangioma.CPT: pharmacometrics & systems pharmacology · 2026Article
- Darbepoetin and Infantile Hemangioma in Premature Infants.Journal of clinical medicine · 2026Article
- Imaging characteristics of parotid gland juvenile capillary hemangioma: A Retrospective analysis of 35 pathologically confirmed cases.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026Article
- A calf with concurrent infantile hemangioma and coronary artery fistula: notes on simultaneous onset.The Journal of veterinary medical science · 2026Article
- Targeted Therapies in Infantile Hemangiomas and Vascular Malformations: From β-Blockers to PI3K/AKT/mTOR Inhibitors.Journal of cellular and molecular medicine · 2026Review
- Bridging the Gap: Infantile Hemangioma Care Variability Among Pediatric Care Physicians in Greece.Cureus · 2026Article
- Prevalence and Risk Factors Associated with the Recurrence of Infantile Hemangiomas After Discontinuation of Propranolol: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2025Review
- Multisystem Infantile Hemangiomatosis with Cutaneous, Hepatic, and Splenic Involvement.Pediatric reports · 2025Article
- Image Sensor-Driven 3D Modeling of Complex Biological Surfaces for Preoperative Planning of Hemangioma Treatment.Sensors (Basel, Switzerland) · 2025Article
- Atypical development and swift resolution of an ulcerated hemangioma: a case report.Journal of medical case reports · 2025Article
- Effects of Notch signaling on proliferation, angiogenesis, and adipogenesis of hemangioma-derived stem cells.European journal of histochemistry : EJH · 2025Article
- A report of 12 cases of congenital hepatic hemangioma and literature review.Frontiers in pediatrics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infantile hemangioma (IH) is the most common pediatric benign vascular tumor. Its pathogenesis is still poorly understood, and it usually appears during the first few weeks of life and follows a characteristic natural course of proliferation and involution. Most IHs are small, benign, resolve spontaneously, and do not require active treatment but only active observation. A minority of IHs are potentially problematic because they can cause life-threatening complications, permanent disfigurement, and functional impairment. Diagnosis is usually clinical, and propranolol is currently the mainstay of treatment. Other therapeutic modalities may be used alone or in combination, depending on the characteristics of the specific IH. New treatment options are being explored every day, and some are showing promising results. It is undeniable that therapeutic modalities for IHs must be selected based on the child's age, the size and location of the lesion, the presence of complications, the implementation conditions, and the possible outcomes of the treatment. The future of IH management will certainly be reflected in improved advanced imaging modalities, research into the genetic and molecular basis, the development of new pharmacological agents or techniques, and the development of standardized protocols, all to optimize outcomes with minimal side effects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.